MedTrace Logo

Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Lung Fluid of Adults With and Without HIV Infection

NCT00371878 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-08-08

No results posted yet for this study

Summary

Lung immune responses are regulated independently of systemic responses. Injected vaccines may induce optimal responses in blood but not at mucosal surfaces. We compared the responses in serum and lung fluid to injected pneumococcal conjugate vaccine.

Conditions

Interventions

BIOLOGICAL

7-valent pneumococcal conjugate vaccine (Prevnar)

Sponsors & Collaborators

  • Kamuzu University of Health Sciences

    collaborator OTHER

  • Liverpool School of Tropical Medicine

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • Royal Liverpool University Hospital

    lead OTHER_GOV

Principal Investigators

  • Neil French, PhD FRCP · Karonga Prevention Study, London School of Tropical Medicine and Hygience

  • Stephen B Gordon, MA MD FRCP · Liverpool School of Tropical Medicine, Liverpool, UK

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-02-28
Completion
2003-10-31

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371878 on ClinicalTrials.gov